January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
1 citations
,
July 2013 in “Clinical Drug Investigation”
14 citations
,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
June 2021 in “F1000Research” Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.
September 2018 in “Translational Andrology and Urology”
Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.
22 citations
,
March 2003 in “Steroids” PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
15 citations
,
July 2019 in “Journal of Biological Inorganic Chemistry” Finasteride helps prevent kidney stones, but side effects need more research.
March 2023 in “Oxford University Press eBooks”
15 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” 5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.
Dutasteride may become the top choice for treating hair loss.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
35 citations
,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
46 citations
,
July 2010 in “Advances in Therapy” SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.
24 citations
,
July 2018 in “Drug Design Development and Therapy” NTF gel improves finasteride delivery for hair loss treatment, reducing side effects.
2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
3 citations
,
April 2021 in “Journal of Medicinal Chemistry” Finasteride may affect PNMT, causing side effects.
January 2024 in “Reproductive toxicology” Hesperidin helps protect against testicular damage caused by finasteride.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.
115 citations
,
January 2001 in “American journal of clinical dermatology” Eflornithine cream effectively reduces women's unwanted facial hair but hair returns if treatment stops.
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
49 citations
,
January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” RU 58841 may treat acne, hair loss, and excessive hair growth.
October 2020 in “Journal of Pharmaceutical Sciences” Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
13 citations
,
February 2013 in “BMJ Case Reports” Stopping finasteride improved seizure control, suggesting neurosteroids affect seizures and treatment.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.